

APPLIED GENETIC TECHNOLOGIES CORP  
Form 8-K  
November 12, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): November 12, 2014**

**APPLIED GENETIC TECHNOLOGIES**  
**CORPORATION**  
**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36370**  
**(Commission**  
  
**File Number)**  
**11801 Research Drive**  
  
**Suite D**

**59-3553710**  
**(IRS Employer**  
  
**Identification No.)**

**Alachua, Florida 32615**

**(Address of Principal Executive Office)**

**Registrant's telephone number, including area code: (386) 462-2204**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition**

On November 12, 2014, Applied Genetic Technologies Corporation issued a press release entitled "AGTC Announces Financial Results for the First Quarter Ended September 30, 2014." The earnings release is furnished as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(c)

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated November 12, 2014, entitled "AGTC Announces Financial Results for the First Quarter Ended September 30, 2014"

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES  
CORPORATION**

Date: November 12, 2014

By: /s/ Lawrence E. Bullock  
Lawrence E. Bullock  
Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated November 12, 2014, entitled AGTC Announces Financial Results for the First Quarter Ended September 30, 2014